疫苗铝佐剂与潜在健康影响的系统综述
该系统综述检索六大数据库及试验注册库(截至2025年11月27日),纳入59项人类研究,评估含铝佐剂疫苗的健康影响。随机对照试验与大型队列的高质量证据一致显示,含铝佐剂疫苗与哮喘、孤独症谱系障碍等严重或长期健康结局无关联;局部持续性结节或肉芽肿少见、自限。
要点
- 含铝佐剂疫苗与严重或长期健康结局无因果关联,结论主要由高质量随机对照试验和队列证据支持。
- 局部持续性结节或肉芽肿少见(<1%)、自限,见于百白破疫苗后,符合迟发型超敏反应。
- 常见不良事件如头痛、肌痛在高质量随机对照试验中未见含铝佐剂配方风险一致性升高。
核心结论
- 当前证据不支持含铝佐剂疫苗与严重或长期健康结局存在因果关联。
- 最常见记录到的反应为不常见、局部、自限的持续性结节或肉芽肿,属超敏反应。
- 巨噬细胞性肌筋膜炎相关研究样本小、方法学受限,未提供可靠因果证据(极低确定性)。
研究设计与样本
- 系统综述,遵循PRISMA 2020指南,检索六大数据库及试验注册库,起始至2023年3月3日,后更新至2025年11月27日。
- 纳入随机对照试验、队列研究、病例系列和生态学研究等评估含铝佐剂疫苗接种后健康结局的人类研究,排除研究性疫苗、病例报告和综述。
- 共纳入59项研究:37项病例系列、11项随机对照试验、9项队列研究、2项生态学研究;两名评价者筛选、提取数据并评估偏倚风险,采用GRADE评级证据确定性。
主要发现
- 随机对照试验和大型队列的高质量证据一致显示含铝佐剂疫苗与哮喘、孤独症谱系障碍或其他慢性疾病等严重或长期健康结局无关联。
- 百白破疫苗后局部持续性结节或肉芽肿少见(<1%,自限;中至低确定性),符合迟发型超敏反应。
- 常见不良事件(如头痛、肌痛)方面,高确定性随机对照试验未发现含铝佐剂配方风险一致性升高;观察到差异时幅度小,以轻至中度为主。
- 证据以方法学受限研究为主,多数病例系列和生态研究存在严重或极严重偏倚风险。
关键数值与推荐
- 局部持续性结节或肉芽肿发生率<1%,自限,见于百白破疫苗后(中至低确定性)。
- 巨噬细胞性肌筋膜炎相关证据确定性为极低。
- 常见不良事件的证据确定性为高(来自随机对照试验)。
临床怎么用
- 向家长和患者解释:现有高质量证据不支持含铝佐剂疫苗导致哮喘、孤独症等严重或长期健康结局。
- 接种百白破疫苗后出现局部持续性结节或肉芽肿罕见且多自限,可按迟发型超敏反应处理并随访。
- 面对常见不良事件(头痛、肌痛)主诉,可说明含铝佐剂配方未见一致性风险升高,按常规对症处理。
局限性
- 部分结局的证据以方法学受限研究为主,多数病例系列和生态研究偏倚风险为严重或极严重。
- 巨噬细胞性肌筋膜炎相关研究普遍样本量小、方法学受限,证据确定性极低。
- 结论主要由较高质量的随机对照试验和队列证据支持,部分结局仍需更高质量研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review and critically appraise human evidence on potential health effects of aluminium adjuvanted vaccines. DESIGN: Systematic review following PRISMA (preferred reporting items for systematic review and meta-analysis) 2020 guidelines. DATA SOURCES: Six databases and trial registries were searched from inception to 3 March 2023 then updated to 27 November 2025. Reference lists of eligible studies were also screened. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Human studies assessing health outcomes after aluminium adjuvanted vaccination, including randomised controlled trials, cohort studies, case series, and ecological studies. Investigational vaccines, case reports, and review articles were excluded. DATA EXTRACTION AND SYNTHESIS: Two reviewers screened studies (with AI assistance for the 2023-25 update), extracted data, and assessed risk of bias (using RoB 2.0, ROBINS-I, or an adapted tool for case series). Certainty of evidence was rated using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). RESULTS: The review included 59 studies (37 case series, 11 randomised controlled trials, nine cohort studies, two ecological studies). High quality evidence from randomised controlled trials and large cohorts consistently showed no association between aluminium adjuvanted vaccines and serious or long term health outcomes, such as asthma, autism spectrum disorders, or other chronic conditions. Studies on macrophagic myofasciitis were generally small and methodologically limited, and did not provide credible evidence of a causal association (very low certainty). Localised persistent nodules or granulomas were observed infrequently after diphtheria-tetanus-pertussis vaccines, consistent with delayed type hypersensitivity (<1%, self-limited; moderate to low certainty). For common adverse events (eg, headache, myalgia), high certainty randomised controlled trials found no consistent increase in risk with aluminium adjuvanted formulations. When differences were observed, they were small and predominantly mild to moderate in severity. Evidence was dominated by methodologically limited studies, with most case series and ecological studies at serious or critical risk of bias. Conclusions are primarily supported by higher quality randomised controlled trials and cohort evidence. CONCLUSIONS: Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. The most consistently documented reactions were persistent nodules or granulomas that are uncommon, local, and self-limited hypersensitivity reactions. These findings are broadly consistent with post-licensure surveillance findings. The predominance of methodologically limited studies for some outcomes highlights the need for higher quality research. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023462831.
引用
- Doyon-Plourde P, Chong J, Abrams EM, et al. Aluminium adjuvants in vaccines and potential health effects: systematic review. BMJ. 2026. PMID: 42091164. doi:10.1136/bmj-2025-088921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。